✦ LIBER ✦

241 REDUCING ALPHA-FETOPROTEIN WITH INTERFERON THERAPY SUPPRESSES HEPATOCARCINOGENESIS IN HEPATITIS C VIRUS-INFECTED PATIENTS WHO ARE VIROLOGICAL RESPONDERS AND NON-RESPONDERS

✍ Scribed by Y. Asahina; K. Tsuchiya; N. Tamaki; M. Sato; T. Tanaka; I. Hirayama; Y. Yasui; K. Ueda; T. Kuzuya; H. Nakanishi; J. Itakura; M. Kurosaki; N. Izumi

Book ID: 117378327
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 74 KB
Volume: 52
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(10)60243-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination therapy of thymalfasin (thym

Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment

✍ VINOD RUSTGI 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB

Long-term Re-treatment with Interferon a

Long-term Re-treatment with Interferon and Ribavirin Combination Therapy in Patients with Chronic Hepatitis C who are Non-responders to Interferon Alone: a Preliminary Study

✍ P. Vega, A. Castro, M. Hermida, S., 📂 Article 📅 1999 🏛 Informa plc 🌐 English ⚖ 139 KB

Effects of the combination of PEG-interf

Effects of the combination of PEG-interferon alpha-2B and ribavirin on the inflammation and fibrosis scores of patients with chronic hepatitis C infection who were virologic non-responders to interferon alpha-2B and ribavirin

✍ Tarek I. Hassanein; Fatma M. Barakat; Cynthia Behling; Wendy Y. Myers; Meghan D. 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 67 KB

Efficacy of low-dose intermittent interf

Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy

✍ Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

## Abstract The efficacy of interferon (IFN) monotherapy for non‐responders to pegylated interferon (PEG‐IFN) plus ribavirin (RBV) combination therapy is still unclear. To evaluate the impact of IFN monotherapy on biochemical response, 200 consecutive patients infected with HCV genotype 1b, who rec